Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz An electric motorcycle ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Ibj.com18h
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly trial update on kidney drug hurts Tectonic
Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.
RFK Jr.’s plan for pharma ads would run straight into the First Amendment
Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...
Apple tops the 2025 World’s Most Admired Companies list for the 18th year in a row
Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.
STAT17h
Pharmalittle: We’re reading about a Super Bowl ad for compounded obesity drugs, a PEPFAR waiver, and more
A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While weight loss is an enormous opportunity, Lilly has a broad portfolio of medications treating many different pockets of the healthcare landscape. Beyond Mounjaro and Zepbound, I'd encourage ...